MacroGenics stock edges lower as biotech analysts highlight risk and upside

Published on 09/19/2026 at 14:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MacroGenics stock trades near USD 1.37 as of September 18, 2026, with analysts on ChartMill seeing an average price target of USD 3.47. The latest data underline both downside from past losses and substantial upside if sentiment improves.

MGNX, US5562221046, Illustration mit AI erstellt.

MacroGenics stock (ISIN US5562221046) is trading at a low single-digit level, with the shares quoted around USD 1.37 on Nasdaq as of September 18, 2026, after a modest decline of 0.72 percent in the last trading session according to data summarized by ChartMill.

Analysts see significant upside from depressed price

According to ChartMill, 13 analysts currently cover MacroGenics stock, with an average price target of USD 3.47 as of September 18, 2026, implying a potential increase of 153.14 percent from the recent price of USD 1.37.

The same overview notes that the stock price declined by 60.86 percent over the past year, underlining how sentiment toward the biotechnology group has weakened markedly compared with prior periods as of September 18, 2026, while the small gain of 0.74 percent over the last month points to only tentative stabilization.ChartMill

Expected swings in earnings and revenue

For MacroGenics, future operating performance is expected to remain volatile, with analysts tracked by ChartMill projecting EPS growth of negative 88.32 percent and revenue growth of negative 57.15 percent for the next year as of September 18, 2026.

These projections suggest that, relative to the latest figures available to analysts at that time, MacroGenics could face sharply lower earnings and a substantial decline in revenue over the coming 12 months, which is a key risk factor investors need to weigh against the apparent upside embedded in the consensus price target.ChartMill

Upcoming earnings date as next catalyst

MacroGenics has a concrete date for its next earnings release, with the company scheduled to report results on March 18, 2026, after the market close, as indicated in the event data compiled by ChartMill.

For investors watching MacroGenics stock ahead of that March 18, 2026 reporting date, the combination of a low market valuation, the consensus price target of USD 3.47 and projections of sharply weaker EPS and revenue underscores that the upcoming earnings release will be a critical checkpoint for reassessing the company’s trajectory.

MacroGenics stock price and valuation snapshot

At a recent price of USD 1.37 on Nasdaq as of September 18, 2026, MacroGenics stock sits far below the average analyst price target of USD 3.47, a gap of 153.14 percent that highlights how strongly the market currently discounts future growth relative to sell-side expectations.ChartMill